Inhibitory effect of daunorubicin enhanced by PDTC on drug-resistant leukemic cells in vitro.
- Author:
Hu-Yi LEI
1
;
Xie-Lan ZHAO
;
Xi-Bin XIAO
Author Information
1. Department of Hematology, Xiangya Hospital, Central Southern University, Changsha 410008, China.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
pharmacology;
Bone Marrow Cells;
drug effects;
pathology;
Cell Proliferation;
drug effects;
Daunorubicin;
pharmacology;
Dose-Response Relationship, Drug;
Drug Resistance, Multiple;
Drug Resistance, Neoplasm;
Drug Synergism;
Humans;
Leukemia;
blood;
pathology;
Leukocytes, Mononuclear;
drug effects;
pathology;
Proline;
analogs & derivatives;
pharmacology;
Thiocarbamates;
pharmacology;
Tumor Cells, Cultured
- From:
Journal of Experimental Hematology
2005;13(3):503-504
- CountryChina
- Language:Chinese
-
Abstract:
To investigate the chemosensitizing effect of pyrroledithiocarbomate (PDTC) on daunorubicin in drug-resistant leukemic cells in vitro, MTT method was used to observe the changes of the proliferation of intractable leukemia MNC treated with daunorubicin (30 microg/ml) combined with PDTC (25, 50 or 100 micromol/L). The results showed that inhibiting rate of daunorubicin combined with PDTC(25, 50 or 100 micromol/L) on drug-resistant leukemic cells was significantly higher than that of daunorubicin alone (P < 0.05). Among the three different doses of PDTC, the concentration of 50 micromol/L of PDTC inhibited the proliferation of drug-resistant leukemic cells significantly. In conclusion, PDTC can sensitize anti-tumor effect of daunorubicin in vitro. The concentration of 50 micromol/L of PDTC has stronger chemosensitizing effect on daunorubicin than that of the other concentrations of PDTC (25 micromol/L or 100 micromol/L) in vitro.
